Abstract: An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.
Abstract: The present invention relates to an emulsifiable concentrate composition, comprising (i) the pesticide tefluthrin; (ii) a solvent for dissolving tefluthrin; (iii) a water-soluble emulsifying surfactant system enabling an oil in water emulsion to be formed when the emulsifiable concentrate composition is diluted with an aqueous solution; (iv) a non-aqueous polar solvent for diluting the water-soluble emulsifying surfactant system; (v) a C2-C10-alcohol to provide physical compatibility between (a) hydrophobic component (ii)) and (b) hydrophilic components (iii) and (iv); to the preparation thereof and to a method of using such a composition to control pests in crops of useful plants.
Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
Type:
Grant
Filed:
June 17, 2016
Date of Patent:
July 12, 2022
Assignee:
CENTURION BIOPHARMA CORPORATION
Inventors:
Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition.
Type:
Grant
Filed:
October 16, 2019
Date of Patent:
July 12, 2022
Assignee:
DIMERIX BIOSCIENCE PTY LTD.
Inventors:
Kevin D. G. Pfleger, Elizabeth McCall, James Williams
Abstract: The present invention relates i.a. to compositions which are suitable for treatment of infertility or subfertility, in particular infertility or subfertility caused by polycystic ovary syndrome (PCOS)or anovulation, or which are suitable for treatment of PCOS or anovulation itself.
Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
June 14, 2022
Assignee:
GW Research Limited
Inventors:
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity.
Abstract: A method is provided for treating a Mendelian disorder of the epigenetic machinery in a subject in need thereof. In particular, the method comprises administering a therapeutically effective amount of an agent that restores balance between open and closed chromatin states at one or more target genes, wherein the agent that restores balance between open and closed chromatin states at one or more target genes is an agent that ameliorates the effect of a defective gene encoding a component of the epigenetic machinery.
Abstract: The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (VSMCs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (VC) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.
Type:
Grant
Filed:
April 19, 2021
Date of Patent:
May 17, 2022
Assignee:
PROGENITY, INC.
Inventors:
Matthew Cooper, Sharat Singh, Karen A. F. Copeland, Lyndal Hesterberg, Amin R. Mazloom, Mohammad Abbasi, Richard Giulio Del Mastro
Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
May 10, 2022
Assignee:
THE BROAD INSTITUTE, INC.
Inventors:
Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
Type:
Grant
Filed:
March 22, 2016
Date of Patent:
May 3, 2022
Assignee:
TASLY PHARMACEUTICAL GROUP CO., LTD.
Inventors:
He Sun, Xijun Yan, Naifeng Wu, Kaijing Yan, Yonghong Zhu, Shunnan Zhang, Xiaolin Bai, Xiaohui Ma, Yi He, Ting Li, Lei Li
Abstract: A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient.
Type:
Grant
Filed:
January 12, 2017
Date of Patent:
April 5, 2022
Assignee:
GRACE THERAPEUTICS INC.
Inventors:
S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
February 22, 2022
Assignee:
Heron Therapeutics, Inc.
Inventors:
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Abstract: Within the scope of the present invention is a new pharmacological strategy for the treatment of tumors based on anti-tumoral immune responses.
Type:
Grant
Filed:
May 2, 2018
Date of Patent:
February 15, 2022
Assignee:
INSTITUT PASTEUR DE MONTEVIDEO
Inventors:
Marcelo Hill, Mercedes Segovia, Sofia Russo, Mathias Jeldres, Maria Romina Girotti, Maite Duhalde Vega, Yamil Damián Mahmoud
Abstract: Compounds, compositions and methods are provided for inhibiting corrosion at a surface in the production, transportation, storage, and separation of fluids such as crude oil and natural gas, the compounds having the formula: wherein: Each R1 is independently —CH2OH and —C(O)OH; R2 is Each R3 is independently hydrogen or R5, or both R3 together form a ring via a linker Each R4 is independently hydrogen or R5; R5 is —CH2SC2H4R1; and n is an integer from 0 to 3.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
February 8, 2022
Assignee:
ChampionX USA Inc.
Inventors:
Jeremy Moloney, Prakasa Rao Anantaneni, Ryan Matthew Harrington
Abstract: The present invention relates to an aqueous ibuprofen and paracetamol composition of pH 6.3-7.3 and to its use. The present invention relates to a method for preparing a combination product of ibuprofen and paracetamol. It also relates to the compositions for use as a medicament, especially for the treatment of pain and/or inflammation; especially for administration of the composition by intravenous injection.
Abstract: An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.
Abstract: The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.